AstraZeneca Iressa Focus Is Sequential Therapy After INTACT Studies Fail

AstraZeneca is looking at Iressa monotherapy as an element of sequential chemotherapy regimens for solid tumors following the failure of the INTACT studies, VP-Medical Director of Oncology George Blackledge told an Aug. 19 conference call

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet